Stockscreener 앱 받기
2.14
4.90%
0.10
시장 영업 전:
2.13
-0.01
-0.47%
전일 마감가:
$2.04
열려 있는:
$2.03
하루 거래량:
213.76K
Relative Volume:
0.07
시가총액:
$13.52M
수익:
-
순이익/손실:
$-11.66M
주가수익비율:
-0.2624
EPS:
-8.156
순현금흐름:
$-11.09M
1주 성능:
-24.38%
1개월 성능:
+65.89%
6개월 성능:
-28.90%
1년 성능:
-65.14%
1일 변동 폭
$2.01
$2.14
1주일 범위
$1.97
$2.91
52주 변동 폭
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
명칭
Phio Pharmaceuticals Corp
전화
(508) 767-3861
주소
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
PHIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.14 | 13.52M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-05 | 개시 | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - Nasdaq
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
Investors’ Faith in Phio Pharmaceuticals Corp (PHIO) could reap rewards if they hold on for the long haul - uspostnews.com
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - MarketScreener
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan
Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com
Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Quantisnow
3 Reasons to Sell PLCE and 1 Stock to Buy Instead - The Globe and Mail
Groundbreaking Cancer Treatment Data: Phio's Dual Immunotherapy Candidates Show Promise - Stock Titan
Phio stock hits 52-week low at $1.22 amid sharp annual decline - Investing.com
Phio stock hits 52-week low at $1.22 amid sharp annual decline By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - TradingView
Phio's Cancer Drug Shows Complete Response as Company Slashes Losses by 33% - Stock Titan
Phio Pharmaceuticals Corp. (PHIO) reports earnings - qz.com
Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Monday - Defense World
PHIO PHARMACEUTICALS CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
PHIOPhio Pharmaceuticals Corp Latest Stock News & Market Updates - Stock Titan
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Quantisnow
Phio Reports 50% Complete Response Rate in Skin Cancer Trial - StockTitan
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile
PHIO stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Australia
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals Corp (PHIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
자본화:
|
볼륨(24시간):